Search results
Results from the WOW.Com Content Network
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...
Tafamidis was approved in the European Union in 2011 for the treatment of transthyretin amyloidosis with polyneuropathy, and in Japan in 2013. [6] [17] In the United States, it was rejected for the treatment of transthyretin amyloidosis with polyneuropathy because the Food and Drug Administration saw insufficient evidence for its efficacy. [20] [7]
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.
Since July 2023, three anti-amyloid medications have been FDA-approved for the treatment of Alzheimer’s disease with more in development. A potential and serious side effect of anti-amyloid ...
Medications during pregnancy must be carefully considered. Many types of drugs, medications, and even nutritional supplements can affect fetal development or cause complications. For over-the-counter and prescription medications, healthcare professionals can help weigh the potential risks and benefits of taking medication while pregnant and if ...
Erenumab, which was developed by Amgen and Novartis, [5] was approved in May 2018, and was the first CGRPR antagonist to be approved by the U.S. Food and Drug Administration. [6] In 2020, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [7] [8]
Eplontersen, sold under the brand name Wainua, is a medication used for the treatment of transthyretin-mediated amyloidosis. [3] It is a transthyretin-directed antisense oligonucleotide. [3] It was developed to treat hereditary transthyretin amyloidosis by Ionis Pharmaceuticals and AstraZeneca. [4] [5] [6] [7]
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.